written on 20.03.2014
Tags:
,

Valeant's CEO, a crackerjack cost-cutter, seeks more 'fat' companies to buy

TAGS: ,

Back in January, Valeant Pharmaceuticals' CEO J. Michael Pearson couldn't say how he intended to reach his lofty goal of cracking the list of top 5 drugmakers worldwide. Now, he's offering new details about his acquisition blueprints, and they include deals in ophthalmology, dermatology and dentistry.

Latest Report